Meanwhile, the phase III VERITAC-3 trial (NCT05909397) is currently assessing the effectiveness of Vepdegestrant paired with palbociclib vs. letrozole plus palbociclib in the first-line treatment for patients with ER+/HER2− advanced breast cancer who have not priorly undergone systemic treatment for their advanced condition. This evidence concerns the gene ERBB2 and breast cancer.